Cumulative GC dose at 12 months:1.8g in both TCZ groups compared to 3.3g and 3.8g in the 2 placebo phase groups (one with a short and one with a long GC tapering course) 52 weeks + Randomized, Ongoing 52 Results available by end of Sirukumab IL-6 blocker 204 GCA, active study weeks 2018 double-blinded open label Relapse free remission at Randomized, GCA, new or 12 12 months: 48% in Langford Abatacept CTLA-4 Ig Full paper multi-centre, 49 relapsing months abatacept vs. 31% in 2015 144 double-blinded control group (p=0.049) Randomized, Study GCA or TAK, 48 Abatacept CTLA-4 Ig 98 Results not yet available completed active months double-blinded Randomized, 52 Estimated completion by Abatacept CTLA-4 Ig Recruiting multi-centre, 200 GCA, new weeks 2021 double-blinded ETN, etanercept; Durat., Duration; GC(s), glucocorticoid(s); GCA, giant cell arteritis; IL, interleukin; mo, months; PMR, polymyalgia rheumatica; PMR-AS, polymyalgia rheumatica activity score; Public., Publication; Ref., Reference; TAK, Takayasu arteritis TCZ, tociliumab; TNF, tumor necrosis factor;
phase Cumulative GC dose at 12 months:1.8g in both TCZ groups compared to 3.3g and 3.8g in the 2 placebo groups (one with a short and one with a long GC tapering course) Sirukumab IL-6 blocker Ongoing study Randomized, double-blinded 204 GCA, active 52 weeks + 52 weeks open label Results available by end of 2018 Abatacept CTLA-4 Ig Full paper Randomized, multi-centre, double-blinded 49 GCA, new or relapsing 12 months Relapse free remission at 12 months: 48% in abatacept vs. 31% in control group (p=0.049) Langford 2015 144 Abatacept CTLA-4 Ig Study completed Randomized, double-blinded 98 GCA or TAK, active 48 months Results not yet available Abatacept CTLA-4 Ig Recruiting Randomized, multi-centre, double-blinded 200 GCA, new 52 weeks Estimated completion by 2021 ETN, etanercept; Durat., Duration; GC(s), glucocorticoid(s); GCA, giant cell arteritis; IL, interleukin; mo, months; PMR, polymyalgia rheumatica; PMR-AS, polymyalgia rheumatica activity score; Public., Publication; Ref., Reference; TAK, Takayasu arteritis TCZ, tociliumab; TNF, tumor necrosis factor;
170706%20Dasgupta_accepted.docx